Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Enterobacterales

ABSTRACT: Whole Genome Sequencing of Carbapenemase-producing Enterobacterales (CPE)

PROVIDER: PRJNA757551 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15695300_1.fastq.gz	Fastqsanger.gz
	SRR15695300_2.fastq.gz	Fastqsanger.gz
	SRR15695400_1.fastq.gz	Fastqsanger.gz
	SRR15695400_2.fastq.gz	Fastqsanger.gz
	SRR15695500_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 1516

Similar Datasets

Enterobacterales

Project description:Whole Genome Sequencing of blaNDM Carbapenemase-producing Enterobacterales (CPE) isolates

| PRJNA765801 | ENA

Enterobacterales

Project description:Long-read Sequencing of Carbapenemase-producing Enterobacterales (CPE) Dataset 1

| PRJNA801415 | ENA

Enterobacterales

Project description:Long-read Sequencing of Carbapenemase-producing Enterobacterales (CPE) Dataset 2

| PRJNA801416 | ENA

Enterobacterales

Project description:Whole genome sequencing of carbapenemase-producing Enterobacterales from patients and hospital sewage

| PRJNA701733 | ENA

Clinical Evaluation of Advanced MALDI-TOF MS for Carbapenemase Subtyping in Gram-negative Isolates

Project description:The spread of carbapenemase-producing Enterobacterales (CPE) is emerging as a significant clinical concern in tertiary hospitals and in particular, long-term care facilities with deficiencies in infection control. This study aims to evaluate an advanced matrix-assisted laser desorption/ionization mass spectrometry (A-MALDI) method for the identification of carbapenemases and further discrimination of their subtypes in clinical isolates. The A-MALDI method was employed to detect CPE target proteins. Enhancements were made to improve detectability and mass accuracy through the optimization of MALDI-TOF settings and internal mass calibration. A total of 581 clinical isolates were analyzed, including 469 CPE isolates (388 KPC, 51 NDM, 40 OXA, and 2 GES) and 112 carbapenemase-negative isolates. Clinical evaluation of the A-MALDI demonstrated 100% accuracy and precision in identifying all the collected CPE isolates. Additionally, A-MALDI successfully discriminated individual carbapenemase subtypes (KPC-2 or KPC-3/4; OXA-48 or OXA-181 or OXA-232; GES-5 or GES-24) and also differentiated co-producing carbapenemase strains (KPC & NDM; KPC & OXA; KPC & GES; NDM & OXA), attributed to its high mass accuracy and simultaneous detection capability. A-MALDI is considered a valuable diagnostic tool for accurately identifying CPE and carbapenemase’s subtypes in clinical isolates. It may also aid in selecting appropriate antibiotics for each carbapenemase subtype. Ultimately, we expect that the A-MALDI method will contribute to preventing the spread of antibiotic resistance and improving human public health.

2024-11-26 | PXD058284 | Pride

Clinical Evaluation of Advanced MALDI-TOF MS for Carbapenemase Subtyping in Gram-negative Isolates

2024-11-25 | PXD046179 | Pride

Enterobacterales

Project description:Whole-genome sequencing of carbapenemase-producing enterobacterales in Toho University Omori Medical Center, Tokyo, Japan

| PRJDB12305 | ENA

Project description:Hybrid assemblies of Carbapenemase-producing Enterobacterales (CPE)

| PRJNA1171009 | ENA

Enterobacterales

Project description:Molecular characterization of carbapenemase-producing Enterobacterales from Czech hospitals

| PRJNA980112 | ENA

Enterobacterales